Radium-223 plus Enzalutamide vs Enzalutamide Alone in Metastatic Castration-Resistant Prostate Cancer – Benjamin Maughan
Benjamin Maughan, MD joins Charles Ryan, MD in a discussion on investigational therapy currently being testing of a combination of enzalutamide and radium-223 compared to enzalutamide alone, both FDA-approved therapies for metastatic castration-resistant prostate cancer (mCRPC). This was a randomized study, patients were randomized to standard of care and enzalutamide or six cycles of radium…
